Genflow Biosciences (LSE:GENF) reported half-year administrative expenses of £454,311 for the six months to 30 June, down from £982,725 in the same period last year.
The London-listed genetic therapy developer, which is working on SIRT6-based treatments for both human and animal health, said the fall was driven by lower research and development costs of £119,445, against £665,862 a year earlier.
Cash reserves stood at £632,553 at the period end, up from £111,792 at 31 December, after the company raised £1.15m net through equity fundraising during the half; Genflow remains debt free.
The period's standout development was the completion of SLAB, Genflow's randomised trial testing its GF-1004 naked DNA construct for healthspan and sarcopenia in aged beagles, which the company had already flagged in September as meeting its primary endpoint through a reduction in biological age versus controls.
"This is a landmark achievement for Genflow, providing strong validation of our SIRT6 cent platform in a real-world aging population," chairman Gad Berdugo said.
On the human health side, Genflow shifted its MASH candidate GF-1002 and other programmes to mRNA-lipid nanoparticle delivery during the half, and launched a glaucoma programme with Iris Pharma and Acuitas incorporating Acuitas' lipid nanoparticle technology for ocular delivery.
Full SLAB trial results, including methylation clock and muscle histology data, are due for presentation at the Animal Longevity Summit in Toronto on 2 October.